Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal ...

New BCR-ABL inhibitors in clinical trials include ABL inhibitors (nilotinib), dual Src family and ABL kinase inhibitors (bosutinib, INNO-404 and AZD0530), non-ATP competitive inhibitors of BCR-ABL ...

"This research highlights the potential of targeting SRC kinase to prevent or overcome multidrug resistance after treatment ...

inhibitors interact with a type of kinase inhibitor that targets the SRC gene to efficiently trigger cell death in AML cells. "Results from this research could add another approach to the ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

Dasatinib is a potent dual Abl/Src inhibitor approved for treatment ... and a relatively short half-life of 3–5 h, tyrosine kinase inhibition is not sustained. However, transient inhibition ...

Currently, five tyrosine kinase inhibitors (TKIs—imatinib, dasatinib, nilotinib, bosutinib, and asciminib) are available for frontline therapy, but no single TKI is optimal for all patients. EUTOS ...

First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors Session Title First-in-Human Phase I Clinical Trials 2 Nuvectis Pharma, Inc. is a ...